{
	"cdmVersionRange" : ">=5.0.0",
	"PrimaryCriteria" : {
		"CriteriaList" : [
			{
				"DrugExposure" : {
					"CodesetId" : 8,
					"DrugTypeExclude" : false
				}
			}
		],
		"ObservationWindow" : {
			"PriorDays" : 0,
			"PostDays" : 0
		},
		"PrimaryCriteriaLimit" : {
			"Type" : "All"
		}
	},
	"ConceptSets" : [
		{
			"id" : 8,
			"name" : "[CDS 793] pembroluzimab_immunotherapy_drug_final",
			"expression" : {
				"items" : [
					{
						"concept" : {
							"CONCEPT_ID" : 45775965,
							"CONCEPT_NAME" : "pembrolizumab",
							"STANDARD_CONCEPT" : "S",
							"STANDARD_CONCEPT_CAPTION" : "Standard",
							"INVALID_REASON" : "V",
							"INVALID_REASON_CAPTION" : "Valid",
							"CONCEPT_CODE" : "1547545",
							"DOMAIN_ID" : "Drug",
							"VOCABULARY_ID" : "RxNorm",
							"CONCEPT_CLASS_ID" : "Ingredient"
						},
						"isExcluded" : false,
						"includeDescendants" : true,
						"includeMapped" : false
					}
				]
			}
		}
	],
	"QualifiedLimit" : {
		"Type" : "First"
	},
	"ExpressionLimit" : {
		"Type" : "All"
	},
	"InclusionRules" : [],
	"EndStrategy" : {
		"CustomEra" : {
			"DrugCodesetId" : 8,
			"GapDays" : 0,
			"Offset" : 0
		}
	},
	"CensoringCriteria" : [],
	"CollapseSettings" : {
		"CollapseType" : "ERA",
		"EraPad" : 0
	},
	"CensorWindow" : {}
}